Latest Articles

wuxi advanced therapies tessa aav scalable production

Pioneering Scalable Solutions in AAV Manufacturing and Testing for Gene Therapy

To launch a successful GMP program for biologics, a robust quality control (QC) release testing protocol is essential. QC testing, which is mandated by global regulatory authorities, helps ensure that a product meets scientific specifications and reaches patients safely. Though each program will have unique parameters, QC testing should gather data to answer the following questions:

All articles

Five Best Practices to Adapt and Improve Quality Control Programs for CGTs

WuXi Advanced Therapies_Analytical Testing_QBD

6 Key Questions to Cover When Selecting Your Cell Banking Manufacturing Partner

WuXi Advanced Therapies 6 Considerations Cell Banking

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI (lifileucel) for Advanced Melanoma

Comercial Manufacturing site in Philadelphia

WuXi Advanced Therapies Supports First Investigational CD19 CAR-T Therapy Approved by China’s NMPA

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

WuXi Advanced Therapies Cabaletta CABA-201

WuXi ATU and T-MAXIMUM Announce Strategic Partnership of Cooperation for MT-027 UCAR-T

Clinical Phase I/II IND Approval! The first cell therapy project in Korea supported by WuXi Advanced Therapies receives MFDS approval

WuXi Advanced Therapies Ticaros Approval

WuXi Advanced Therapies Announces Licensing Agreement with Janssen

WuXi Advanced Therapies TESSA AAV Janssen

WuXi Advanced Therapies Testing Facility To Receive EMA GMP Certificate for New Philadelphia Facility

WuXi Advanced Therapies R400 Philadelphia

Upcoming Events

See All Events
Sep 17
Boston, MA
CAR-TCR Summit Boston
Sep 18
Basel, Switzerland
Nordic Life Science Days (NLS)
Sep 23
Boston, MA
Bio Process Intl (BPI) C&GT Commercialization
Ameba Creative StudioAmeba Creative Studio